Nabriva Therapeutics plc - Ordinary Shares (NBRV) News
Filter NBRV News Items
NBRV News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest NBRV News From Around the Web
Below are the latest news stories about NABRIVA THERAPEUTICS PLC that investors may wish to consider to help them evaluate NBRV as an investment opportunity.
Nabriva (NBRV) Posts Positive Data From Cystic Fibrosis StudyNabriva (NBRV) posts positive top-line data from the phase I study evaluating oral and intravenous Xenleta (lefamulin) in adult patients with cystic fibrosis. Shares down. |
Nabriva's antibiotic shows promise as a potential cystic fibrosis treatmentThe Phase 1 study is testing the safety of oral and intravenous versions of lefamulin, the active ingredient in Xenleta, in adult patients with the condition. |
Nabriva's stock is up after sharing antibiotic newsShares of Nabriva Therapeutics Plc were up 13.8% in premarket trading on Monday after the company said in a news release it had positive data from a Phase 1 clinical trial assessing its antibiotic as a treatment for cystic fibrosis. The drug, Xenleta, is approved to treat community-acquired bacterial pneumonia. Nabriva plans to share more details from the open-label CF study in the first half of next year. The company's stock has tumbled 85.5% this year, while the broader S&P 500 is down 15.5%. |
Nabriva Therapeutics Announces Positive Topline Results from Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis- PK Data and Safety Profile Consistent with Previous Studies in Healthy Subjects – - Results Support Potential Utility of Lefamulin in Patients with Cystic Fibrosis - DUBLIN, Ireland and FORT WASHINGTON, Pa., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced positive topline results from their Phase 1 clinical trial that |
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Nabriva (NBRV) and Venus Concept (VERO)Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Nabriva (NBRV – Research Report) and Venus Concept (VERO – Research Report). Nabriva (NBRV) H.C. Wainwright analyst Ed Arce maintained a Hold rating on Nabriva today. The company's shares closed last Thursday at $2.18, close to its 52-week low of $2.04. According to TipRanks. |
Montgomery County biopharmaceutical firm reducing workforce by 40%Nabriva Therapeutics, a biopharmaceutical company with operations in Fort Washington and Ireland, said Thursday it is reducing its workforce by 40% and pivoting its focus to commercializing its skin and skin structure infections antibiotic while it explores "strategic options" for its future. Nabriva (NASDAQ: NBRV) will focus on Sivextro, an antibiotic used to treat skin and skin structure infections, that it has been selling exclusively in the United States under a licensing deal with Merck since mid-2020. “Given the pressures of the macro environment, we believe building on our commercial success with Sivextro, as demonstrated by the continued prescription demand growth, is the most efficient and effective way to extend our cash runway and preserve optionality and value for our shar... |
Nabriva Therapeutics Pivoting Strategic Focus Reports Third Quarter Financial Results and Provides Corporate Update- Shifted Focus to SIVEXTRO to Enable Cost Cutting - - Cash Runway Extended into Q1 2023 - - Q3 2022 Total Revenue of $9.2 Million - - Engaged Torreya Capital As Strategic Advisor - - Conference call today at 4:30 p.m. Eastern Time - DUBLIN, Ireland, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced it has pivoted i |
Nabriva Therapeutics to Report Third Quarter 2022 Financial Results and Recent Corporate Highlights on November 10, 2022DUBLIN, Ireland and FORT WASHINGTON, Pa., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its third quarter financial results along with recent company highlights after the close of the U.S. financial markets on Thursday, November 10, 2022. Nabriva’s management will host a conference call at 4: |
Rigetti (RGTI) Stock Pops on New Quantum Computing PartnersRigetti (RGTI) stock is getting a boost on Friday after the company revealed it found new partners for its quantum computing efforts. |
What Is Going on With Nabriva Therapeutics (NBRV) Stock Today?Nabriva Therapeutics (NBRV) stock caught the attention of traders on Friday after shares surged in price early this morning. |